Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 677-682 , December 2008

Advances in the clinical management of GVHD

  • James L.M. Ferrara, MD (Director)

      Affiliations

    • Corresponding Author InformationDepartments of Pediatrics and of Internal Medicine, the University of Michigan Medical School, Comprehensive Cancer Center, 1500 E. Medical Center Drive, SPC 5942, Room 6308, Ann Arbor, MI 48109-5942, USA. Tel.: +1 734 615 1340; Fax: +1 734 615 3947.

References 

  1. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematological Oncology. 2003;21:149–161
  2. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Reviews. 2003;17:187–194
  3. Hill GR, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. Journal of Clinical Investigation. 1999;104:459–467
  4. Choi SW, Kitko CL, Braun T, et al. Change in plasma Tumor Necrosis Factor Receptor 1 levels in the first week post-myeloablative allogeneic transplant correlates with severity and incidence of GVHD and survival. Blood. May 23 2008;[Epub ahead of print]
  5. Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008;111:2470–2475
  6. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biology of Blood and Marrow Transplantation. 2002;8:387–394
  7. Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. Journal of Intensive Care Medicine. 2004;19:320–334
  8. Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004;104:649–654
  9. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003;102:2768–2776
  10. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006;107:4177–4181
  11. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood. 2006;108:749–755
  12. Hintermeier-Knabe R, Brockhaus M, Holler E, et al. Sequential release of tumor necrosis factor alpha and tumor necrosis factor receptors in complications of human bone marrow transplantation. In:  Freund M,  Link H,  Schmidt RE,  Welte K editor. Cytokines in hemopoiesis, oncology, and AIDS, II. Berlin: Springer-Verlag; 1992;p. 443–448
  13. Paczesny S, Choi S, Braun T, et al. A four protein plasma fingerprint of acute graft versus host disease (GVHD) predicts long term survival. Blood. 2007;110:38;[ASH Annual Meeting Abstracts]
  14. Combination of etanercept, mycophenolate mofetil (MMF), denileukin diftitox (Ontak), and pentostatin with steroids. http://clinicaltrials.gov/ct2/show/NCT004741492008;

PII: S1521-6926(08)00059-5

doi: 10.1016/j.beha.2008.07.003

Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 677-682 , December 2008

Article Tools

* Image Usage & Resolution